{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:39:26Z","timestamp":1790627966827,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100223","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T14:38:21Z","timestamp":1628606301000},"page":"100223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review"],"prefix":"10.1016","volume":"6","author":[{"given":"I.","family":"Solares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-3270","authenticated-orcid":false,"given":"D.","family":"Vi\u00f1al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morales-Conejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rodriguez-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2021.100223_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"3 Pt 1","key":"10.1016\/j.esmoop.2021.100223_bib2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.105.3.608","article-title":"Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children","volume":"105","author":"DeBella","year":"2000","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100223_bib3","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100223_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A\u00a0RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2021.100223_bib5","series-title":"GeneReviews\u00ae","article-title":"Neurofibromatosis 1. 1998 October 2","author":"Friedman","year":"1993"},{"key":"10.1016\/j.esmoop.2021.100223_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.esmoop.2021.100223_bib7","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/cancers12010114","article-title":"An update on neurofibromatosis type 1-associated gliomas","volume":"12","author":"Lobbous","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100223_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmoop.2021.100223_bib10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100223_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2021.100223_bib12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.esmoop.2021.100223_bib13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.24873","article-title":"Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.esmoop.2021.100223_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100223_bib15","first-page":"289","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas","volume":"19","author":"Jakacki","year":"2017","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100223_bib16","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","author":"Gross","year":"2020","journal-title":"Childs Nerv Syst"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100223_bib17","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2021.100223_bib18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2021.100223_bib19","first-page":"10","article-title":"Selumetinib in children with clinically asymptomatic inoperable nf1 related plexiform neurofibromas","volume":"67","author":"Glassberg","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100223_bib20","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1200\/JCO.2020.38.15_suppl.3612","article-title":"Phase II trial of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886 hydrogen sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"38","author":"O\u2019Sullivan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100223_bib22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100223_bib23","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: a phase I\/IIa study","volume":"36","author":"McCowage","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2021.100223_bib24","doi-asserted-by":"crossref","first-page":"iii420","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"NFB-17. MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1-associated plexiform neurofibromas: a report from PNOC and the NF clinical trials consortium","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100223_bib25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","article-title":"Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a Phase 2a Trial","volume":"139","author":"Zehou","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A\u00a0phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100223_bib35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100223_bib36","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT) [published correction appears in J Clin Oncol. 2018 Dec 10;36(35):3528]","volume":"36","author":"Carvajal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100223_bib37","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdx628","article-title":"SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer","volume":"28","author":"Soria","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib38","first-page":"vdaa095","article-title":"The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas","volume":"2","author":"Jackson","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100223_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience","volume":"147","author":"Esp\u00edrito Santo","year":"2020","journal-title":"J\u00a0Neurooncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100223_bib40","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100223_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"Choueiri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100223_bib42","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100223_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11060-017-2723-2","article-title":"PedsQL neurofibromatosis type 1 module for children, adolescents and young adults: feasibility, reliability, and validity","volume":"137","author":"Nutakki","year":"2018","journal-title":"J\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100223_bib45","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100223_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-011-1620-1","article-title":"Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer","volume":"68","author":"Boasberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100223_bib47","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100223_bib48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100223_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100223_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2021.100223_bib52","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1158\/1078-0432.CCR-20-1696","article-title":"Pediatric PK\/PD phase I trial of pexidartinib in relapsed and refractory leukemias and solid tumors including neurofibromatosis type I-related plexiform neurofibromas","volume":"26","author":"Boal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100223_bib53","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100223_bib54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2021.100223_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-017-0579-4","article-title":"Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies","volume":"19","author":"Schoumacher","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100223_bib56","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100223_bib57","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0039-1691830","article-title":"Trametinib induces neurofibroma shrinkage and enables surgery","volume":"50","author":"Vaassen","year":"2019","journal-title":"Neuropediatrics"},{"issue":"23","key":"10.1016\/j.esmoop.2021.100223_bib58","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","article-title":"Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100223_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/0008-5472.CAN-20-1992","article-title":"Activation of receptor tyrosine kinases mediates acquired resistance to MEK inhibition in malignant peripheral nerve sheath tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:26Z","timestamp":1761856046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2059702921001848"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100223","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100223"}}